Calithera Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-06-01
- Employees
- 10
- Market Cap
- $487
- Website
- http://www.calithera.com
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 444
- Registration Number
- NCT03428217
- Locations
- 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
🇺🇸Orchard Healthcare Research, Inc., Skokie, Illinois, United States
🇺🇸University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 28
- Registration Number
- NCT03370302
- Locations
- 🇨🇳
National Taiwan-University Hospital, Taipei, Taiwan
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo-To, Japan
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Registration Number
- NCT03359733
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 43
- Registration Number
- NCT03357627
- Locations
- 🇨🇦
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Registration Number
- NCT03338881
A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)
- Conditions
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 17
- Registration Number
- NCT03238651
- Locations
- 🇯🇵
NHO Nagoya Medical Center, Nagoya-shi, Aichi, Japan
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 69
- Registration Number
- NCT03163667
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸University Cancer & Blood Center, LLC, Athens, Georgia, United States
🇺🇸Florida Cancer Specialists- North, Saint Petersburg, Florida, United States
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 49
- Registration Number
- NCT03123393
- Locations
- 🇺🇸
Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
🇮🇹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
🇫🇷Hopital Haut-Leveque, Pessac Cedex, Aquitaine, France
Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 52
- Registration Number
- NCT03057600
- Locations
- 🇺🇸
University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Winship Cancer Institute - Emory University, Atlanta, Georgia, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 14
- Registration Number
- NCT02944435
- Locations
- 🇺🇸
Algorithme Pharma USA, LLC, Fargo, North Dakota, United States